Keywords
How to Cite
Abstract
The effectiveness of the new therapeutic approach aimed at the destruction of the cancer cell community was evaluated on the immortalized human glioblastoma cell line U87. Initially, the reference elements of a new strategy for eradication of tumor-initiating stem cells were characterized. The main points of the strategy were as follows. 1) Evaluation of the TAMRA+ (tumor-initiating stem cells) presence in the population of U87 culture cells. 2) Determination of the reference time points of the DNA interstrand cross-links repair, induced by cross-linking cytostatics mitomycin C. 3) Determination of the day after initiation of therapy when TAMRA+ cells accumulate and are synchronously present in the G1/S sensitive for the treatment phase of the cell cycle. Based on the data obtained, a therapeutic regimen aimed at eradicating TAMRA+ cells (tumor-initiating stem cells) was identified. Treatment of the culture was carried out by cross-linking cytostatic mitomycin C and complex DNA preparation. Transplantation experiments showed that high experimental doses of mitomycin C (20 μg/ml) totally destroy transplantation potential of U87 cells. Diminution of mitomycin C to therapeutic doses (5 μg/ ml) clearly demonstrated effect of complex double-stranded DNA preparation to reducing of U87 tumorigenic potential. These fully confirmed the concept of developed cancer treatment technology.References
Брюховецкий А.С., Шевченко В.Е., Чехонин В.П. и др. Сравнительное протеомное картирование опухолевых стволовых клеток, выделенных из глиобластомы линии u87, нейрональных стволовых и мультипотентных мезенхимных стромальных клеток человека: от каталогизации клеточных белков к инновационной парадигме протеом-основанной клеточной терапии опухолей // Клеточная трансплантология и тканевая инженерия. - 2013. -Т. 8. - № 2. - С. 84-91.
Брюховецкий И.С. Клеточные и постгеномные технологии в терапии мультиформной глиобластомы // Тихоокеанский медицинский журнал. - 2015. - Т. 2. - С. 12-17.
Брюховецкий И.С., Дюйзен И.В., Шевченко В.Е., Хотимченко Ю.С. Стволовые клетки глиобластомы индуцируют миграцию нормальных стволовых клеток // Тихоокеанский медицинский журнал. - 2016. - Т. 2. - С. 81-89.
Лихачева А.С., Рогачев В.А., Николин В.П., и др. Участие экзогенной ДНК в молекулярных процессах, протекающих в соматической клетке // Информационный вестник ВОГиС. - 2008. - Т. 12. - № 3. - С. 426-473.
Никифорова З.Н., Кудрявцев И.А., Арноцкая Н.Е., и др. Опухолевые стволовые клетки мультиформной глиобластомы // Успехи молекулярной онкологии. - 2016. - Т. 3. - С. 26-33.
Поттер Е.А., Долгова Е.В., Минкевич А.М., и др. Терапевтические эффекты воздействия циклофосфана, препаратов двуцепочечной ДНК и их сочетания на раковые клетки асцита Кребс-2 и различные формы трансплантатов // Вавиловский журнал генетики и селекции. - 2016. - Т. 20. - № 1. - С. 96-107.
Поттер Е.А., Долгова Е.В., Минкевич А.М., и др. Характеристика режимов терапевтического воздействия циклофосфана и препаратов двуцепочечной ДНК на опухоль Кребс-2, растущую в асцитной форме, приводящих к эрадикации первичного асцита // Вавиловский журнал генетики и селекции. - 2016. - Т 20. - № 1. - С. 108-124.
Поттер Е.А., Долгова Е.В., Минкевич А.М., и др. Режим однократной инъекции препарата двуцепочечной ДНК после каждой инъекции циклофосфана, приводящий к эрадикации первичного асцита Кребс-2 // Вавиловский журнал генетики и селекции. - 2016. - Т 20. - № 5. - С. 716-722.
Поттер Е.А., Долгова Е.В., Проскурина А.С., и др. Разработка регламента терапевтического режима, основанного на синергичном действии циклофосфана и препаратов двуцепочечной ДНК, приводящего к полному вылечиванию экспериментальных животных от асцитной формы опухоли мыши Кребс-2 // Вавиловский журнал генетики и селекции. - 2016. - Т. 20. - № 5. - С. 723-735.
Alyamkina E.A., Nikolin V.P., Popova N.A., et al. Combination of cyclophosphamide and double-stranded DNA demonstrates synergistic toxicity against established xenografts // Cancer Cell Int. - 2015. - Vol. 15. - P. 32.
Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response // Nature. - 2006. - Vol. 444. - № 7120. - P. 756-760.
Bae K.-M., Dai Y., Vieweg J., Siemann D.W. Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation // Am. J. Cancer Res. - 2016. - Vol. 6. - № 5. - P. 1078-1088.
Beier D., Hau P., Proescholdt M., et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles // Cancer Res. - 2007. - Vol. 67. - № 9. - P. 4010-4015.
Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell // Nat Med. - 1997. - Vol. 3. - P. 730-737.
Brescia P., Richichi C., Pelicci G. Current strategies for identification of glioma stem cells: adequate or unsatisfactory? // J Oncol. - 2012. - Vol. 2012. - P. 376894.
Brescia P., Ortensi B., Fornasari L., et al. CD133 is essential for glioblastoma stem cell maintenance // Stem Cells. - 2013. - Vol. 31. - № 5. - P. 857-869.
Chang J.C. Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance // Medicine (Baltimore). - 2016. - Vol. 95. - № 1 Suppl 1. - P. S20-S25.
Chen J., Kesari S., Rooney C., et al. Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres // Genes Cancer. - 2010. - Vol. 1. - № 8. - P. 822-835.
Dayem A.A., Choi H.-Y., Kim J.-H., Cho SG. Role of oxidative stress in stem, cancer, and cancer stem cells // Cancers (Basel). - 2010. - Vol. 2. - № 2. - P. 859-884.
Dolgova E.V., Proskurina A.S., Nikolin V.P., et al. "Delayed death" phenomenon: A synergistic action of cyclophosphamide and exogenous DNA // Gene. - 2012. - Vol. 495. - P. 134-145.
Dolgova E.V., Efremov Y.R., Orishchenko K.E., et al. Delivery and processing of exogenous double-stranded DNA in mouse CD34+ hematopoietic progenitor cells and their cell cycle changes upon combined treatment with cyclophosphamide and double-stranded DNA // Gene. - 2013. - Vol. 528. - № 2. - P. 74-83.
Dolgova E.V., Alyamkina E.A., Efremov Y.R., et al. Identification of cancer stem cells and a strategy for their elimination // Cancer Biol Ther. - 2014. - Vol. 15. - № 10. - P. 1378-1394.
Dolgova EV, Mishinov SV, Proskurina AS, et al. Novel cancer stem marker and its applicability for grading primary human gliomas // Technol Cancer Res Treat. - 2018. - Vol. 17. - P. 1533034617753812.
Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents // N Engl J Med. - 2000. - Vol. 343. - № 19. - P. 1350-1354.
Fan X., Khaki L., Zhu T.S., et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts // Stem Cells. - 2010. - Vol. 28. - № 1. - P. 5-16.
Friedman H.S., Kerby T., Calvert H. Temozolomide and treatment of malignant glioma // Clin Cancer Res. - 2000. - Vol. 6. - № 7. - P. 2585-2597.
Garcia-Casas A., Garcia-Olmo D.C., Garcia-Olmo D. Further the liquid biopsy: Gathering pieces of the puzzle of genometastasis theory // World J. Clin. oncol. - 2017. - Vol. 8. - № 5. - P. 378-388.
Gilbert C.A., Ross A.H. Glioma stem cells: cell culture, markers and targets for new combination therapies // Cancer stem Cells theories and Practice. - 2011. - Vol. 108. - № 5. - P. 1031-1038.
Gopal K., Gupta N., Zhang H., et al. oxidative stress induces the acquisition of cancer stem-like phenotype in breast cancer detectable by using a sox2 regulatory region-2 (sRR2) reporter // oncotarget. - 2016. - Vol. 7. - № 3. - P. 3111-3127.
Gottesman M.M. Mechanisms of cancer drug resistance // Annu. Rev. Med. - 2002. - Vol. 53. - № 1. - P. 615-627.
Hanada K., Budzowska M., Modesti M. et al. the structure-specifi c endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into double-strands breaks // EMBo J. - 2006. - Vol. 25. - № 20. - P. 4921-4932.
Iida H., suzuki M., Goitsuka R., Ueno H. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and soX2 // Int. J. oncol. - 2012. - Vol. 40. - № 1. - P. 71-79.
Jiang W.G., sanders A.J., Katoh M., et al. tissue invasion and metastasis: Molecular, biological and clinical perspectives // semin. Cancer Biol. - 2015. - Vol. 35. - P. s244-s275.
Jinesh G.G., Kamat A.M. Blebbishield emergency program: an apoptotic route to cellular transformation // Cell Death Differ. - 2016. - Vol. 23. - № 5. - P. 757-758.
Karle P., Renner M., salmons B., Günzburg W.H. necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide // Cancer Gene Ther. - 2001. - Vol. 8. - № 3. - P. 220-230.
Kase M., Minajeva A., Niinepuu K., et al. Impact of CD133 positive stem cell proportion on survival in patients with glioblastoma multiforme // Radiol oncol. - 2013. - Vol. 47. - № 4. - P. 405-410.
Kim E.H., Song H.S., Yoo S.H., Yoon M. tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis // oncotarget. - 2016. - Vol. 7. - № 40. - P. 65125-65136.
Konar S.K., Bir S.C., Maiti IK., Nanda A. A systematic review of overall survival in pediatric primary glioblastoma multiforme of the spinal cord // J Neurosurg Pediatr. - 2016. - Vol. 19. - № 2. - P. 239-248.
Lagasse E. Cancer stem cells with genetic instability: the best vehicle with the best engine for cancer // Gene Ther. - 2008. - Vol. 15. - № 2. - P. 136-142.
Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into sCID mice // Nature. - 1994. - Vol. 367. - P. 645-648.
Liu Y., Liu X., Chen L., et al. Targeting glioma stem cells via the Hedgehog signaling pathway // Neuroimmunol Neuroinflammation. - 2014. - Vol. 1. - № 2. - P. 51-59.
Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system // Adv Drug Deliv Rev. - 2012. - Vol. 64. - № 7. - P. 614-628.
McNeill K.A. Epidemiology of brain tumors // Neurol Clin. - 2016. - Vol. 34. - № 4. - P. 981-998.
Pietras A., Katz A.M., Ekström E.J., et al. osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes andpromotes aggressive tu mor growth // Cell stem Cell. - 2014. - Vol. 14. - № 3. - P. 357-369.
Potter E.A., Dolgova E.V., Proskurina A.s., et al. A strategy to eradicate well-developed Krebs-2 ascites in mice // oncotarget. - 2016. - Vol. 7. - № 10. - P. 11580-11594.
Potter EA, Dolgova EV, Proskurina As, et al. Gene expression profiling of tumor-initiating stem cells from mouse Krebs-2 carcinoma using a novel marker of poorly differentiated cells // oncotarget. - 2017. - Vol. 8. - № 6. - P. 9425-9441.
Qiang L., Yang Y., Ma Y., et al. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines // Cancer Letters. - 2009. - Vol. 279. - P. 13-21.
Ramirez Y.P., Weatherbee J.L., Wheelhouse R.T., Ross A.H. Glioblastoma multiforme therapy and mechanisms of resistance // Pharmaceuticals (Basel). - 2013. - Vol. 6. - № 12. - P 1475-1506.
Reya T., Morrison S.J., Clarke M.F., Weissman IL. stem cells, cancer, and cancer stem cells // Nature. - 2001. - Vol. 414. - № 6859. - P. 105-111.
Saijo H., Hirohashi Y., Torigoe T., et al. Plasticity of lung cancer stem-like cells is regulated by the transcription factor HoXA5 that is induced by oxidative stress // oncotarget. - 2016. - Vol. 7. - № 31. - P 50043-50056.
Schreck K.C., Taylor P., Marchionni L., et al. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance // Clin Cancer Res. - 2010. - Vol. 16. - № 24. - P. 6060-6070.
Shindo H., Ogura T., Masuno T., et al. Induction of activated macrophages by intraperitoneal injection of mitomylin C in mice // Cancer Immunol Immunother. - 1985. - Vol. 20. - № 2. - P 145-150.
Siney E.J., Holden A., Casselden E., et al. Metalloproteinases ADAM10 and ADAM17 mediate migration and differentiation in glioblastoma sphere-forming cells // Mol Neurobiol. - 2016. - Vol. 54. - № 5. - P 3893-3905.
Smith M.A., Freidlin B., Gloeckler Ries L.A., Simon R. Trends in reported incidence of primary malignant brain tumors in children in the United states // Journal of the National Cancer Institute. - 1998. - Vol. 90. - № 17. - P 1269-1277.
Song X., Dilly A.K., Kim S.Y, et al. Rapamycin-enhanced mitomycin C-induced apoptotic death is mediated through the s6K1-Bad-Bak pathway in peritoneal carcinomatosis // Cell Death Dis. - 2014. - Vol. 5. - P. e1281.
Stamatakos G.S., Antipas V.P., Uzunoglu N.K. simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo // Comput Biol Med. - 2006. - Vol. 36. - № 11. - P. 1216-1234.
Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma // N Engl J Med. - 2005. - Vol. 352. - № 10. - P. 987-996.
Takezaki T., Hide T., Takanaga H,.et al. Essential role of the Hedgehog signaling pathway in human glioma-initiating cells // Cancer sci. - 2011. - Vol. 102. - № 7. - P 1306-1312.
Wang Y., Xu C., Du L.Q., et al. Evaluation of the Comet Assay for Assessing the Dose-Response Relationship of DNA Damage Induced by Ionizing Radiation // Int J Mol sci. - 2013. - Vol. 14. - № 11. - P 22449-22461.
Wei K.C., Huang C.Y, Chen P.Y, et al. Evaluation of the prognostic value of CD44 in glioblastoma multiforme // Anticancer Res. - 2010. - Vol. 30. - № 1. - P. 253-259.
Zhang N., Liu X., Li L., Legerski R. Double-strand breaks induce homologous recombinational repair of interstrand cross-links via cooperation of MSH2, ERCC1-XPF, REV3, and the Fanconi anemia pathway // DNA Repair. - 2007. - Vol. 6. - № 11. - P. 1670-1678.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019